Articles with public access mandates - Roy ChemalyLearn more
Not available anywhere: 6
Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review
EJ Ariza-Heredia, L Nesher, RF Chemaly
Cancer letters 342 (1), 1-8, 2014
Mandates: US National Institutes of Health
Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience
D El-Haddad, F El Chaer, J Vanichanan, DP Shah, EJ Ariza-Heredia, ...
Antiviral research 134, 58-62, 2016
Mandates: US National Institutes of Health
Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients
A Abudayyeh, A Hamdi, M Abdelrahim, H Lin, VD Page, G Rondon, ...
Transplant Infectious Disease 19 (1), e12632, 2017
Mandates: US National Institutes of Health
Postoperative urinary tract infection quality assessment and improvement: the STOP UTI program and its impact on hospitalwide CAUTI rates
N Narula, HA Lillemoe, AS Caudle, RF Chemaly, JJ Anderson, C Segal, ...
The Joint Commission Journal on Quality and Patient Safety 45 (10), 686-693, 2019
Mandates: US National Institutes of Health
Viral therapeutics: where we are and where we are going
RF Chemaly, TW Clark
Current opinion in infectious diseases 31 (6), 512-513, 2018
Mandates: National Institute for Health Research, UK
Reply to Giménez et al
L El Haddad, E Ariza-Heredia, RF Chemaly
The Journal of infectious diseases 219 (9), 1512-1513, 2019
Mandates: US National Institutes of Health, Government of Spain
Available somewhere: 89
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ...
Science 359 (6371), 97-103, 2018
Mandates: US National Science Foundation, US National Institutes of Health
Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation
FM Marty, P Ljungman, RF Chemaly, J Maertens, SS Dadwal, RF Duarte, ...
New England Journal of Medicine 377 (25), 2433-2444, 2017
Mandates: US National Institutes of Health
A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID‐19) pandemic: an international collaborative group
HO Al‐Shamsi, W Alhazzani, A Alhuraiji, EA Coomes, RF Chemaly, ...
The oncologist 25 (6), e936-e945, 2020
Mandates: National Medical Research Council, Singapore
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation
RF Chemaly, AJ Ullmann, S Stoelben, MP Richard, M Bornhäuser, ...
New England Journal of Medicine 370 (19), 1781-1789, 2014
Mandates: US National Institutes of Health
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
A Sharma, NS Bhatt, A St Martin, MB Abid, J Bloomquist, RF Chemaly, ...
The Lancet Haematology 8 (3), e185-e193, 2021
Mandates: US Department of Defense, US National Institutes of Health
Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled …
DJ Winston, JAH Young, V Pullarkat, GA Papanicolaou, R Vij, E Vance, ...
Blood, The Journal of the American Society of Hematology 111 (11), 5403-5410, 2008
Mandates: US National Institutes of Health
Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies
RF Chemaly, DP Shah, MJ Boeckh
Clinical infectious diseases 59 (suppl_5), S344-S351, 2014
Mandates: US National Institutes of Health
The role of the healthcare environment in the spread of multidrug-resistant organisms: update on current best practices for containment
RF Chemaly, S Simmons, C Dale Jr, SS Ghantoji, M Rodriguez, J Gubb, ...
Therapeutic advances in infectious disease 2 (3-4), 79-90, 2014
Mandates: US National Institutes of Health
A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation
FM Marty, DJ Winston, RF Chemaly, KM Mullane, TB Shore, ...
Biology of Blood and Marrow Transplantation 25 (2), 369-381, 2019
Mandates: US National Institutes of Health
How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients
F El Chaer, DP Shah, RF Chemaly
Blood, The Journal of the American Society of Hematology 128 (23), 2624-2636, 2016
Mandates: US National Institutes of Health
Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial
RK Avery, S Alain, BD Alexander, EA Blumberg, RF Chemaly, ...
Clinical Infectious Diseases 75 (4), 690-701, 2022
Mandates: US National Institutes of Health, Danish Council for Independent Research
Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials
RF Chemaly, S Chou, H Einsele, P Griffiths, R Avery, RR Razonable, ...
Clinical Infectious Diseases 68 (8), 1420-1426, 2019
Mandates: US National Institutes of Health, Danish National Research Foundation …
Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections
DP Shah, SS Ghantoji, JN Shah, KK El Taoum, Y Jiang, U Popat, ...
Journal of antimicrobial chemotherapy 68 (8), 1872-1880, 2013
Mandates: US National Institutes of Health
The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia
JR Galloway‐Peña, DP Smith, P Sahasrabhojane, NJ Ajami, ...
Cancer 122 (14), 2186-2196, 2016
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program